Inmagene Bio charts backdoor to U.S. listing with offshore acquisition
The biotech company’s merger with Ikena Oncology will bring in $175 million in fresh funds, including $75 million from an oversubscribed private placement Key Takeaways: Inmagene Bio plans to merge…
Recent Articles
RELATED ARTICLES
-
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US -
Seyond may get stuck in slow-moving SPAC lane to Hong Kong listing
7855.HK
-
ZG Group set to forge Hong Kong’s second De-SPAC listing
2572.HK
- Youlife chases SPAC listing after death of Hong Kong IPO
-
CATL to recharge its offshore output with new shares
300750.SHE
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK
